

Pharmaceutical Pipeline – Key Events in 2018*

Potential Approvals US/EU

ERLEADA™ (apalutamide)	– Non-metastatic prostate cancer (US)	✓
JULUCA® (Ralpivirine+dolutegravir FDC ViiV)	– HIV (EU)	✓
SYMTUZA™	– HIV (US)	
DARZALEX®	– Frontline multiple myeloma non-transplant (US✓/EU)	
XARELTO®	– CAD/PAD (US)	
INVOKANA®	– CANVAS/CANVAS-R–CV outcome (US/EU)	
ZYTIGA®	– Hormone-naïve metastatic prostate cancer (US)	✓
IMBRUVICA®	– Treatment-naive WM combo w/rituximab (US)^^	

Planned Submissions US/EU

Esketamine	– Treatment-resistant depression (US/EU)	
Erdafitinib	– Solid tumors (US)	
XARELTO®	– Congestive heart failure (US)	
ERLEADA™ (apalutamide)	– Non-metastatic prostate cancer (EU)	✓
IMBRUVICA®	– DLBCL frontline (US/EU) – Frontline CLL combo w/obinutuzumab (US/EU) – Treatment-naive WM combo w/rituximab (US✓/EU)	
OPSUMIT®	– Chronic thromboembolic PH (US ✓/EU)	
TREMFYA®	– Psoriasis Patient-Controlled Injector (US / EU)	✓

Potential Clinical Data Presentations

Phase 3

XARELTO®	– VTE prevention medically ill pts (MARINER) – Congestive heart failure (COMMANDER)	
STELARA®	– Ulcerative Colitis	
Esketamine	– Treatment-resistant depression	✓
ERLEADA™ (apalutamide)	– Non-metastatic prostate cancer (SPARTAN)	✓
DARZALEX®	– Frontline multiple myeloma non-transplant (MAIA)^	
SYMTUZA™	– HIV	
IMBRUVICA®	– Frontline CLL combo w/obinutuzumab (ILLUMINATE) – DLBCL frontline (PHOENIX) – Treatment-naive WM combo w/rituximab (iINNOVATE)	✓

Potential Clinical Data Presentations

Phase 2

HIV Vaccine	– HIV (TRAVERSE)	✓
IMBRUVICA®	– DLBCL relapsed (PCYC1123) – Frontline CLL (IV fixed duration) (PCYC1142)	✓ ✓
DARZALEX®	– Frontline multiple myeloma transplant (GRIFFIN) MRD and safety	✓
Erdafitinib	– Metastatic urothelial cancer (BLC2001)	✓

✓ = Achieved

* This information is accurate as of July 17, 2018 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.